Our Portfolio

Avery Therapeutics, Inc. is a pre-clinical stage company developing regenerative therapeutics. Avery’s lead product, MyCardia, is a tissue-engineered graft for the treatment of chronic heart failure, a disease affecting 24 million people worldwide.